Jacobs & Co. CA lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,534 shares of the medical equipment provider’s stock after selling 300 shares during the period. Jacobs & Co. CA’s holdings in Zimmer Biomet were worth $5,528,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ZBH. Amundi Pioneer Asset Management Inc. boosted its position in shares of Zimmer Biomet by 1.3% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 117,666 shares of the medical equipment provider’s stock valued at $15,025,000 after buying an additional 1,465 shares during the period. United Bank boosted its holdings in shares of Zimmer Biomet by 10.1% in the third quarter. United Bank now owns 10,165 shares of the medical equipment provider’s stock valued at $1,384,000 after purchasing an additional 933 shares during the period. Peapack Gladstone Financial Corp boosted its holdings in shares of Zimmer Biomet by 2.5% in the third quarter. Peapack Gladstone Financial Corp now owns 6,330 shares of the medical equipment provider’s stock valued at $862,000 after purchasing an additional 154 shares during the period. Lombard Odier Asset Management Europe Ltd purchased a new stake in shares of Zimmer Biomet in the third quarter valued at approximately $282,000. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Zimmer Biomet by 38.4% in the third quarter. Point72 Asset Management L.P. now owns 378,582 shares of the medical equipment provider’s stock valued at $51,540,000 after purchasing an additional 105,031 shares during the period. Institutional investors and hedge funds own 87.17% of the company’s stock.

Shares of ZBH traded up $2.16 during trading hours on Thursday, reaching $164.91. 3,710 shares of the company traded hands, compared to its average volume of 1,258,443. The stock has a market capitalization of $34.35 billion, a P/E ratio of 1,017.25, a P/E/G ratio of 4.32 and a beta of 1.34. The company has a quick ratio of 1.02, a current ratio of 2.18 and a debt-to-equity ratio of 0.67. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.68 and a 12-month high of $170.05. The business has a fifty day moving average price of $160.20 and a 200-day moving average price of $151.65.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 4th. The medical equipment provider reported $2.11 earnings per share for the quarter, beating analysts’ consensus estimates of $2.06 by $0.05. Zimmer Biomet had a net margin of 0.52% and a return on equity of 10.07%. The firm had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.08 billion. During the same period in the previous year, the company earned $2.30 earnings per share. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 4.8 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 30th. Shareholders of record on Monday, March 29th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.58%. The ex-dividend date of this dividend is Friday, March 26th. Zimmer Biomet’s payout ratio is 12.20%.

A number of analysts recently issued reports on the company. Morgan Stanley boosted their price target on Zimmer Biomet from $170.00 to $180.00 and gave the company an “overweight” rating in a report on Monday, February 8th. Piper Sandler boosted their price target on Zimmer Biomet from $185.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, February 5th. JMP Securities boosted their price objective on shares of Zimmer Biomet from $165.00 to $180.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. BTIG Research boosted their price objective on shares of Zimmer Biomet from $160.00 to $173.00 and gave the stock a “buy” rating in a research note on Monday, January 25th. Finally, Needham & Company LLC boosted their price objective on shares of Zimmer Biomet from $185.00 to $192.00 and gave the stock a “strong-buy” rating in a research note on Friday, February 5th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Zimmer Biomet presently has an average rating of “Buy” and a consensus target price of $165.65.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.

See Also: What are different types of coverage ratios?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.